Clinical Trial Update: Afatinib in Advanced Refractory Urothelial Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of afatinib in advanced refractory urothelial cancer was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Cancer of the Ureter
• Urethral Cancer
• Urothelial Cancer

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: University of Chicago | Conditions: Distal Urethral Cancer, Proximal Urethral Cancer | Phase 2 | Status: TERMINATED | Results posted: 2025-04-25